Development of a novel score for early detection of hepatocellular carcinoma among high-risk hepatitis C virus patients

Tumor Biology

Volumn 35, Issue 7, 2014, Pages 6501-6509

  El Mezayen, Hatem A ^a   Darwish, Hossam ^b  

^a Helwan University   (Egypt)

^b Damietta Cancer Institute   (Egypt)

Author keywords

Cirrhosis; Diagnosis; HCV; Hepatocellular carcinoma; Tumor markers

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; AMINOTRANSFERASE; BIOLOGICAL MARKER; VASCULOTROPIN;

ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS C; HEPATITIS C VIRUS; HEPATOCELLULAR CARCINOMA VASCULAR ENDOTHELIAL GROWTH FACTOR SCORE; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MIDDLE AGED; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT;

ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; EARLY DETECTION OF CANCER; FEMALE; FIBROSIS; HEPACIVIRUS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PLATELET COUNT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84905001502     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1858-4     Document Type: Article

References (39)

1. Nafee AM, Pasha HF, Abd El Aal SM, Mostafa NA. Clinical significance of serum clusterin as a biomarker for evaluating diagnosis and metastasis potential of viral-related hepatocellular carcinoma. Clin Biochem. 2012;45:1070-4.
2. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011;54:463-71.
3. Gonzalez SA, Keeffe EB. Diagnosis of hepatocellular carcinoma: role of tumor markers and liver biopsy. Clin Liver Dis. 2011;15:297-306.
4. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-30. (Pubitemid 32844200)
5. Chen L, Ho DW, Lee NP, et al. Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker. Ann Surg Oncol. 2010;17:2518-25.
6. Hao K, Luk JM, Lee NP, et al. Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer. 2009;9:389.
7. Kew MC. Hepatocellular carcinoma in developing countries: Prevention, diagnosis and treatment. World J Hepatol. 2012;4:99-104.
8. Mukozu T, Nagai H, Matsui D, Kanekawa T, Sumino Y. Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma. Anticancer Res. 2013;33:1013-1021.
9. Yoshiji H, Kuriyama S, Hicklin DJ, et al. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology. 1999;30:1179-86. (Pubitemid 29510856)
10. Moon WS, Rhyu KH, Kang MJ, et al. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol. 2003;16:552-7. (Pubitemid 36718436)
11. Soresi M, Magliarisi C, Campagna P, et al. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res. 2003;23:1747-53. (Pubitemid 36750842)
12. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825-32. (Pubitemid 27129209)
13. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-26. (Pubitemid 36919874)
14. Anzola M. Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepat. 2004;11:383-93. (Pubitemid 39336219)
15. Giannelli G, Fransvea E, Trerotoli P, et al. Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients. Clin Chim Acta. 2007;383:147-52. (Pubitemid 47016463)
16. Lehman EM, Wilson ML. Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis. Int J Cancer. 2009;124:690-7.
17. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29:502-10.
18. Camma C, Cabibbo G. Prognostic scores for hepatocellular carcinoma: none is the winner. Liver Int. 2009;29:478-80.
19. Harris SR, Schoeffner DJ, Yoshiji H, Thorgeirsson UP. Tumor growth enhancing effects of vascular endothelial growth factor are associated with increased nitric oxide synthase activity and inhibition of apoptosis in human breast carcinoma xenografts. Cancer Lett. 2002;179:95-101. (Pubitemid 34195658)
20. El-Mezayen HA, el Toson SA, Darwish H, El-Badry E. Discriminant function based on parameters of hyaluronic acid metabolism and nitric oxide to differentiate metastatic from non-metastatic colorectal cancer patients. Tumour Biol. 2012;33:995-1004.
21. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;359:845-8.
22. Mise M, Arii S, Higashituji H, et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology. 1996;23:455-64. (Pubitemid 26087158)
23. Suzuki K, Hayashi N, Miyamoto Y, et al. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res. 1996;56:3004-9. (Pubitemid 26199745)
24. Matsumata T, Kanematsu T, Takenaka K, Yoshida Y, Nishizaki T, Sugimachi K. Patterns of intrahepatic recurrence after curative resection of hepatocellular carcinoma. Hepatology. 1989;9:457-60. (Pubitemid 19074982)
25. El-Zayadi AR, Badran HM, Barakat EM, et al. Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol. 2005;11:5193-8. (Pubitemid 41410338)
26. Yeh SH, Chen PJ, Lai MY, Chen DS. Allelic loss on chromosomes 4q and 16q in hepatocellular carcinoma: associationwith elevated alpha-fetoprotein production. Gastroenterology. 1996;110:184-92.
27. Kojiro M. Pathological evolution of early hepatocellular carcinoma. Oncology. 2002;62 Suppl 1:43-7. (Pubitemid 34702019)
28. Sherman M, Klein A. AASLD single-topic research conference on hepatocellular carcinoma: Conference proceedings. Hepatology. 2004;40:1465-73. (Pubitemid 39657024)
29. Marrero JA, Lok AS. Newer markers for hepatocellular carcinoma. Gastroenterology. 2004;127:S113-9. (Pubitemid 39423378)
30. Attallah AM, Omran MM, Attallah AA, et al. HCC-ART score, a simple, highly sensitive and specific test for early diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Br J Cancer. 2013;109:1657-65.
31. Fliser D, Zurbruggen I, Mutschler E, et al. Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int. 1999;55:629-34. (Pubitemid 29082889)
32. Djousse L, Rothman KJ, Cupples LA, Levy D, Ellison RC. Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring Study. Circulation. 2002;106:2919-24. (Pubitemid 35424742)
33. Masuzaki R, Tateishi R, Yoshida H, et al. Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography. J Clin Gastroenterol. 2008;42:839-43.
34. Attallah AM, El-Far M, Abdel Malak CA, et al. Evaluation of cytokeratin-1 in the diagnosis of hepatocellular carcinoma. Clin Chim Acta. 2011;412:2310-5.
35. Dai CY, Ho CK, Huang JF, et al. Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan. J Hepatol. 2009;52:160-166.
36. Saad WE, Darwish WM, Davies MG, et al. Transjugular intrahepatic portosystemic shunts in liver transplant recipients: technical analysis and clinical outcome. AJR Am J Roentgenol. 2013;200:210-8.
37. Daskalow K, Rohwer N, Raskopf E, et al. Role of hypoxia-inducible transcription factor 1alpha for progression and chemosensitivity of murine hepatocellular carcinoma. J Mol Med (Berl). 2010;88:817-27.
38. Tangkijvanich P, Tosukhowong P, Bunyongyod P, et al. Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand. Southeast Asian J Trop Med Public Health. 1999;30:110-4.
39. Bachtiar I, Santoso JM, Atmanegara B, et al. Combination of alpha-1-acid glycoprotein and alpha-fetoprotein as an improved diagnostic tool for hepatocellular carcinoma. Clin Chim Acta. 2009;399:97-101.